STELLAR-009, NCT06191796: Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 25 | US | zanzalintinib, XL092, AB521, Nivolumab, OPDIVO® | Exelixis, Arcus Biosciences, Inc. | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | 01/26 | 01/27 | | |
